Treatment of Kaposi's Sarcoma in Acquired Immunodeficiency Syndrome with an Alternating Vincristine-vinblastine Regimen
Overview
Authors
Affiliations
Twenty-four patients with acquired immunodeficiency syndrome and Kaposi's sarcoma (KS) were treated with a regimen alternating vincristine with vinblastine on a weekly basis. Objective responses to this regimen were observed in nine patients (45%), and seven (35%) had stabilization of progressive KS. Few toxic effects were observed. Alternating vincristine-vinblastine therapy is well-tolerated and effective palliative treatment for KS in acquired immunodeficiency syndrome.
Diagnosis and Treatment of Kaposi's Sarcoma.
Saif M Resid Staff Physician. 2022; 47(13):19-24.
PMID: 35450139 PMC: 9020379.
Stabilization of vinca alkaloids encapsulated in poly(lactide-co-glycolide) microspheres.
Marinina J, Shenderova A, Mallery S, Schwendeman S Pharm Res. 2000; 17(6):677-83.
PMID: 10955840 DOI: 10.1023/a:1007522013835.
A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma.
Nasti G, Errante D, Santarossa S, Vaccher E, Tirelli U Drug Saf. 1999; 20(5):403-25.
PMID: 10348092 DOI: 10.2165/00002018-199920050-00002.
Drug treatment of HIV-related opportunistic infections.
Klepser M, Klepser T Drugs. 1997; 53(1):40-73.
PMID: 9010648 DOI: 10.2165/00003495-199753010-00004.
Goebel F, Goldstein D, Goos M, Jablonowski H, Stewart J Br J Cancer. 1996; 73(8):989-94.
PMID: 8611437 PMC: 2075823. DOI: 10.1038/bjc.1996.193.